Malathy Subramanian

Title: Malathy Subramanian: Innovator in Pharmaceutical Formulations

Introduction

Malathy Subramanian is a notable inventor based in Fremont, CA (US). She has made significant contributions to the field of pharmaceutical formulations, particularly in the development of stable liquid formulations for therapeutic antibodies. Her work has the potential to enhance the efficacy and stability of important medical treatments.

Latest Patents

Malathy holds a patent for "Stable aqueous pharmaceutical formulations of daclizumab antibodies." This invention is directed to a stable liquid pharmaceutical formulation comprising a high concentration, e.g., 50 mg/ml or more, of antibody in about 20-60 mM succinate buffer or 30-70 mM histidine buffer, having a pH from about 5.5 to about 6.5, about 0.01-0.1% polysorbate, and a tonicity modifier that contributes to the isotonicity of the formulation. This liquid formulation is stable at refrigerated temperature (2-8°C) for at least 1 year, and preferably 2 years. It is suitable for subcutaneous injection and includes preferred antibodies such as Daclizumab, a humanized anti-IL-2 receptor monoclonal antibody, among others.

Career Highlights

Throughout her career, Malathy has worked with prominent companies in the biotherapeutics sector, including AbbVie Biotherapeutics Inc. and Abbott Biotherapeutics Corporation. Her experience in these organizations has allowed her to contribute to the advancement of innovative pharmaceutical solutions.

Collaborations

Malathy has collaborated with talented professionals in her field, including Elizabet Kaisheva and Supriya Gupta. These collaborations have fostered a productive environment for innovation and development in pharmaceutical research.

Conclusion

Malathy Subramanian's contributions to pharmaceutical formulations exemplify the impact of innovation in healthcare. Her patent for stable aqueous formulations demonstrates her commitment to improving therapeutic options for patients.